Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 11/20 | 0.51 |
| ▸ | BRS3 | P32247 | 2/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28067401 | 0.91 | LTB4R2 (0.56) | LTB4R2BRS3LPAR1 | |
| SCHEMBL5041952 | 0.82 | TSHR (0.57) | — | |
| SCHEMBL28358608 | 0.81 | LTB4R2 (0.57) | LTB4R2LPAR1 | |
| SCHEMBL28067445 | 0.79 | RXRA (0.62) | LTB4R2 | |
| SCHEMBL22227462 | 0.79 | LTB4R2 (0.51) | LTB4R2BRS3LPAR1 | |
| SCHEMBL5151244 | 0.79 | LTB4R2 (0.60) | LTB4R2BRS3LPAR1 | |
| SCHEMBL231282 | 0.78 | TSHR (0.61) | — | |
| SCHEMBL18759613 | 0.78 | HNF4A (0.63) | LTB4R2 | |
| SCHEMBL30292805 | 0.78 | HNF4A (0.63) | LTB4R2 | |
| SCHEMBL6799282 | 0.77 | MCL1 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0973537-A4 | COCAETHYLENE IMMUNOGENS AND ANTIBODIES | DRUGABUSE SCIENCES S A S (FR) | 2004-12-01 | — | — | EP | disclosed |
| US-6541004-B1 | Cocaethylene immunogens and antibodies | DRUGABUSE SCIENCES, INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020102659-A1 | Cocaethylene immunogens and antibodies | DRUGABUSE SCIENCES S.A.S. (FR) | 2002-08-01 | — | — | US | disclosed |
| US-6114508-A | 2-CARBOXYETHYL-3-BENZOYLOXY-N-METHYLTROPANE DERIVATIVES; COCAINE DETOXIFICATION; VACCINES | DRUGABUSE SCIENCES, INC. (US) | 2000-09-05 | — | — | US | disclosed |
| EP-0973537-A1 | COCAETHYLENE IMMUNOGENS AND ANTIBODIES | DrugAbuse Sciences S.A.S. (FR) | 2000-01-26 | — | — | EP | disclosed |
| US-5817770-A | N-METHYLTROPANE, 2-CARBOXYETHYL- OR N-ETHYLCARBOXAMIDE, 3-BENZOYLOXY- OR BENZAMIDO- | DRUG ABUSE SCIENCES, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| WO-1998042359-A1 | COCAETHYLENE IMMUNOGENS AND ANTIBODIES | DRUG ABUSE SCIENCES, INC. (US) | 1998-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102659-A1 | Cocaethylene immunogens and antibodies | CES2, BCHE, ERP44 | LTB4R2 3053/4885BRS3 411/4885LPAR1 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.